Horizon Health: Antibody Therapies for Emerging Viruses
Funds €9–10M projects that turn monoclonal antibodies into prevention and treatment options for one emerging virus.
Emerging and re-emerging viral infections can become global health threats quickly, especially as climate change alters where viruses spread. This topic funds research that moves existing monoclonal antibody candidates closer to prevention and treatment.
A proposal must choose one emerging virus and stay focused on it. The work can complete laboratory characterisation, test protective effects in …
Advance existing prophylactic and therapeutic monoclonal antibody candidates against exactly one named virus: Ebola, Marburg, Crimean-Congo Hemorrhagic Fever, Rift Valley Fever, Enterovirus D68 or Chikungunya. Work covers in-vitro characterisation, animal-model protection testing, antibody-dependent enhancement risk, GMP batch production and first-in-human clinical safety studies. Proposals should engage regulators, use relevant research infrastructures and address sex, age, ethnicity and disability in clinical work.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up